Diagnostic and prognostic significance of survivin levels in malignant pleural effusion Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Diagnostic value of procalcitonin and C-reactive protein in the differentiation among bening and malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
The diagnostic value of pleural fluid C-reactive protein level in pleural effusions Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002
Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004
Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003
Prognostic significance of neutrophil predominance in pleural fluid in patients with malignant effusion Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
Diagnostic usefulness of tumour markers in pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
The diagnostic value of CA-125 in pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 386s Year: 2001
The use of pleural fluid C-reactive protein level, as a diagnostic marker for pleural effusions Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009
Diagnostic significance of ADAM8 in non-small cell lung cancer and malignant pleural effusion Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
C-reactive protein in differentiation between tuberculous and malignant pleural effusions Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011
Prognostic value of treatment outcomes patients with malignant pleural mesothelioma Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Diagnostic value of C-reactive protein in exudative pleural effusions Source: International Congress 2019 – Clinical problems Year: 2019
Utility of pleural fluid for predictive marker testing in malignant pleural effusion Source: Virtual Congress 2020 – Malignant pleural effusion in 2020: understanding the biology and clinical implications Year: 2020
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007